Loading
Life sciences · Journal article
Scientific Reports · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Uveal melanoma (UM) is the most common intraocular malignancy in adults, and despite great advances in combination drug therapies based on UM-related pathways, targeted therapies remain an unmet medical need, and there has been a decrease in sensitivity to chemotherapy. Astragalus, as a medicinal and edible herbs, may play a role in the treatment of cancer by combining different chemotherapeutic agents. In this study, we first found that Astragalus can be combined with dacarbazine for the treatment of uveal melanoma using a hormonal mouse model and determined that the transcription factor TEAD may be one of the reasons for the reduced sensitivity of uveal melanoma to dacarbazine chemotherapy. Subsequently, using a multidisciplinary approach of computer-aided drug design combined with cellular experiments and molecular pairing, we found that RISO, a compound in Astragalus, stabilised the binding of YAP/TEAD, reduced the expression of the downstream pathway proteins CCN1, CTGF and CARP, promoted the reduction of mitochondrial membrane potential in 92.1 cells, and induced apoptosis and cell cycle arrest in 92.1 cells, which had a synergistic effect with dacarbazine. Moreover, the integration of molecular dynamics simulations with energy analysis identified (R)-isomontanol as a promising inhibitor. The identification of key hydrophobic residues is of paramount importance, as these residues have been shown to be crucial for TEAD-ligand interactions. Furthermore, these residues have been demonstrated to exhibit both high binding stability and the strongest pharmacological potential when compared to the other investigated compounds. This provides valuable insights for the design of more potent TEAD inhibitors in future studies. These findings provide new ideas and drugs for the treatment of UM. Bridging the gap in research on the interaction of Astragalus with transcription factors.